J Appl Biomed 10:177-186, 2012 | DOI: 10.2478/v10136-012-0012-0

Cilostazol suppresses LPS-stimulated maturation of DC2.4 cells through inhibition of NF-κB pathway

Tianhua Chen1, Zhiliang Li1,*, Qiang Fu1, Linlin Chen1, Longxing Cao1, Weiwei Zhang1, Jianxin Diao2
1 Department of Cardiology, The Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, P. R. China
2 Symptomatic Laboratory of Traditional Chinese Medical, Southern Medical University, Guangzhou, P. R. China

Cilostazol is a phosphodiesterase-3 inhibitor that functions as a platelet aggregation inhibitor and is used for treating peripheral artery diseases and ischemic stroke. Dendritic cells (DCs) play an active role in the immunological processes related to atherosclerosis. Cilostazol has anti-atherogenic and anti-inflammatory effects, but the effects of cilostazol on DC maturation remain unknown. The purpose of this study was to determine the effects of cilostazol on lipopolysaccharide (LPS)-induced maturation of DCs. DC2.4 cells were treated with cilostazol for 12 h and subsequently stimulated with LPS to induce maturation. Cilostazol reduced the expression of maturation-associated markers induced by LPS, such as CD40, CD86, and MHCII, improved the endocytotic function, and decreased production of the tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) of these cells. To further elucidate the mechanisms responsible for the inhibition of DC2.4 maturation by cilostazol, we investigated the effect of cilostazol on LPS-stimulated nuclear factor-kappa B (NF-κB) activation. Our results indicated that cilostazol treatment decreased IκBα degradation and inhibited NF-κB p65 translocation, and the inhibitory effects of cilostazol were cAMP-independent. Therefore, inhibition of NF-κB by cilostazol might result in the suppression of DC maturation. In conclusion, cilostazol suppressed LPS-stimulated DC maturation, which might contribute to its anti-atherosclerosis effect.

Keywords: atherosclerosis; cilostazol; dendritic cells; lipopolysaccharide; nuclear factor-κB

Received: January 3, 2012; Revised: February 12, 2012; Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chen T, Li Z, Fu Q, Chen L, Cao L, Zhang W, Diao J. Cilostazol suppresses LPS-stimulated maturation of DC2.4 cells through inhibition of NF-κB pathway. J Appl Biomed. 2012;10(4):177-186. doi: 10.2478/v10136-012-0012-0.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aicher A, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeler S. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation. 107: 604-611, 2003. Go to original source... Go to PubMed...
    2. An H, Yu Y, Zhang M, Xu H, Qi R, Yan X, Liu S, Wang W, Guo Z, Guo J, Qin Z, Cao X. Involvement of ERK, p38 and NF-κB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology. 106: 38-45, 2002. Go to original source... Go to PubMed...
    3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 392: 245-252, 1998. Go to original source... Go to PubMed...
    4. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol. 18: 767-811, 2000. Go to original source... Go to PubMed...
    5. Berger J, Slapničková M. Circadian structure of rat neutrophil phagocytosis. Comp Clin Path. 12: 84-89, 2003. Go to original source...
    6. Bobryshev YV. Dendritic cells and their involvement in atherosclerosis. Curr Opin Lipidol. 11: 511-517, 2000. Go to original source... Go to PubMed...
    7. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J. 26: 1700-1704, 2005. Go to original source... Go to PubMed...
    8. Bobryshev YV, Lord RS. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol. 58: 307-322, 1995a. Go to original source... Go to PubMed...
    9. Bobryshev YV, Lord RS. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res. 29: 689-696, 1995b. Go to original source...
    10. Bobryshev YV, Lord, RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immuneinflammatory reactions. Cardiovasc Res. 37: 799-810, 1998. Go to original source... Go to PubMed...
    11. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 267: 1485-1488, 1995. Go to original source... Go to PubMed...
    12. Cao W, Bobryshev YV, Lord RS, Oakley RE, Lee SH, Lu J. Dendritic cells in the arterial wall expresses C1q: potential significance in atherogenesis. Cardiovasc Res. 60: 175-186, 2003. Go to original source... Go to PubMed...
    13. Fu RH, Hran HJ, Chu CL, Huang CM, Liu SP, Wang YC, Lin YH, Shyu WC, Lin SZ. Lipopolysaccharide-stimulated activation of murine DC2.4 cells is attenuated by n-butylidenephthalide through suppression of the NF-kappaB pathway. Biotechnol Lett. 33: 903-910, 2011. Go to original source... Go to PubMed...
    14. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 199: 1607-1618, 2004. Go to original source... Go to PubMed...
    15. Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A, Wang K, Zou Y, Chen H. Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol. 25: 2157-2163, 2005. Go to original source... Go to PubMed...
    16. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y. Cilostazol stroke prevention study: a placebo-controlled double blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 9: 147-157, 2000. Go to original source... Go to PubMed...
    17. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 352: 1685-1695, 2005. Go to original source... Go to PubMed...
    18. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 91: 281-291, 2002. Go to original source... Go to PubMed...
    19. Jung WK, Lee DY, Park C, Choi YH, Choi I, Park SG, Seo Sk, Lee SW, Yea SS, Ahn SC, Lee CM, Park WS, Ko GH, Choi IW. Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol. 159: 1274-1285, 2010. Go to original source... Go to PubMed...
    20. Kaisho T, Tanaka T. Turning NF-kappaB and IRFs on and off in DC. Trends Immunol. 29: 329-336, 2008. Go to original source... Go to PubMed...
    21. Kambayashi T, Wallin RP, Ljunggren HG. cAMP-elevating agents suppress dendritic cell function. J Leukoc Biol. 70: 903-910, 2001. Go to original source... Go to PubMed...
    22. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittel-Forsch. 35: 1144-1149, 1985.
    23. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther. 313: 502-509, 2005. Go to original source... Go to PubMed...
    24. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 42: 145-151, 2008. Go to original source... Go to PubMed...
    25. Ludewig B, Zinkernagel RM, Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc Med. 12: 154-159, 2002. Go to original source... Go to PubMed...
    26. Park SY, Lee SW, Baek SH, Lee SJ, Lee WS, Rhim BY, Hong KW, Kim CD. Induction of heme oxygenase-1 expression by cilostazol contributes to its anti-inflammatory effects in J774 murine macrophages. Immunol Lett. 136: 138-145, 2011. Go to original source... Go to PubMed...
    27. Park WS, Jung WK, Lee DY, Moon C, Yea SS, Park SG, Seo SK, Park C, Choi YH, Kim GY, Choi JS, Choi IW. Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-kappaB inactivation: not involved in cAMP mechanisms. Int Immunopharmacol. 10: 1077-1085, 2010. Go to original source... Go to PubMed...
    28. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity. 21: 733-741, 2004. Go to original source... Go to PubMed...
    29. Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra-Bilen J, Cybulsky MI. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res. 106: 383-390, 2010. Go to original source... Go to PubMed...
    30. Perrin-Cocon L, Coutant F, Agaugue S, Deforges S, André P, Lotteau V. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J Immunol. 167: 3785-3791, 2001. Go to original source... Go to PubMed...
    31. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial dieases: a critical review. Am J Med. 112: 49-57, 2002. Go to original source... Go to PubMed...
    32. Reis ESC. Dendritic cells in a mature age. Nat Rev Immunol. 6: 476-483, 2006. Go to original source... Go to PubMed...
    33. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med. 188: 2175-2180, 1998. Go to original source... Go to PubMed...
    34. Rhule A, Rase B, Smith JR, Shepherd DM. Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by Panax notoginseng. J Ethnopharmacol. 116: 179-186, 2008. Go to original source... Go to PubMed...
    35. Ross R. Atherosclerosis - an inflammatory disease?N Engl J Med. 340: 115-126, 1999. Go to original source... Go to PubMed...
    36. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 158: 2723-2730, 1997. Go to original source...
    37. Soilleux EJ, Morris LS, Trowsdale J, Coleman N, Boyle JJ. Human atherosclerotic plaques express DC-SIGN, a novel protein found on dendritic cells and acrophages. J Pathol. 198: 511-516, 2002. Go to original source... Go to PubMed...
    38. Takase H, Hashimoto A, Okutsu R, Hirose Y, Ito H, Imaizumi T, Miyakoda G, Mori T. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittel-Forsch. 57: 185-191, 2007. Go to original source... Go to PubMed...
    39. Tsai CS, Lin FY, Cheng YH, Yang TL, Wang HJ, Huang GS, Lin CY, Tsai YT, Lin SJ, Li CY. Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem. 103: 54-66, 2008. Go to original source... Go to PubMed...
    40. Wang S, Yan C, Xu H, Zhao X, Han Y. Suppression of encephalitogenic T-cell responses by cilostazol is associated with upregulation of regulatory T cells. Neuroreport. 21: 629-635, 2010. Go to original source... Go to PubMed...
    41. Wick G, Xu Q. Atherosclerosis - an autoimmune disease. Exp Gerontol. 34: 559-566, 1999. Go to original source...

    Return to the content